Skip to content

Assessment of Retinal Microcirculation in Patients With Type 1 Diabetes Mellitus

Assessment of Retinal Microcirculation in Patients With Type 1 Diabetes Mellitus

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07705321
Enrollment
100
Registered
2026-07-15
Start date
2025-06-01
Completion date
2026-09-30
Last updated
2026-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Type 1, Diabetic Complications, Diabetic Retinopathy, Microvascular Circulation, Retinal Microvascular Disease

Brief summary

Type 1 diabetes mellitus (T1DM) is associated with an increased lifetime risk of developing diabetic retinopathy, a leading cause of visual impairment among working-age adults worldwide. Retinal assessment plays a pivotal role in the management of patients with T1DM, as the retina provides a unique, non-invasive window into the body's microvascular circulation. Early detection of retinal abnormalities is essential because structural and microvascular changes may develop years before the onset of vision-threatening diabetic retinopathy or visual symptoms. Contemporary retinal imaging techniques, enable the quantitative evaluation of retinal microvasculature allowing the identification of subclinical retinal damage.

Interventions

A non-invasive retinal imaging technique that provides high-resolution visualization and quantitative assessment of the retinal and choroidal microvasculature, including vessel density and the foveal avascular zone, without the use of intravenous dye.

Sponsors

University of Athens
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Adults aged 18 years or older. 2. Diagnosis of Type 1 diabetes mellitus (T1DM) according to the American Diabetes Association (ADA) criteria. 3. Ability and willingness to provide written informed consent.

Exclusion criteria

1. Active uveitis or other intraocular inflammatory disease. 2. Uncontrolled glaucoma 3. High myopia (spherical equivalent refractive error \>5.0 diopters) 4. History of ocular trauma. 5. History of intraocular surgery within the previous 6 months.

Design outcomes

Primary

MeasureTime frame
Quantitative assessment of retinal vessel density measured by optical coherence tomography angiography (OCTA).Vessel density will be assessed at baseline using OCTA. This is a cross-sectional study; no follow-up assessments will be performed. Participants will be evaluated at a single study visit and classified according to the stage of diabetic retinopathy.

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 16, 2026